Meet the researchers working on regenerative neuroscience in Merja Voutilainen’s Lab.
I am a pharmacologist and neuroscientist specialized in preclinical research of neurodegenerative diseases.
As a principle investigator, I am running a research group which studies CDNF/MANF family of neurotrophic factors. We are mainly focused on Amyotrophic lateral sclerosis (ALS) and Parkinson’s disease and are trying to find neurorestorative treatments that promote functional recovery.
My research focus is modelling neurodegenerative diseases (Amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD)) with patient specific human induced pluripotent stem cell–derived neurons in vitro. The effect and functional mechanisms of the novel neurotrophic factor CDNF is studied in these models, in order to investigate the potential of CDNF for the treatment of ALS and PD.
My background is in stem cell research and neuronal differentiation. I joined the team in the beginning of 2018, after defending my PhD dissertation from the University of Tampere.
My research focus is the neuroprotectional effect of growth factors in neurodegenerative disease models, such as Parkinson’s disease and ALS. I am also especially interested in the mode of action of growth factors in glial cells and neurons.
I got my Bachelor Degree in Biotechnology from the University of Milan in 2012. I then decided to move to Finland to study Neuroscience at the University of Helsinki, where I got my Master Degree in 2014. Since my studies, I realized my deep interest for neurodegenerative diseases and I was excited to join Mart and Merja's work on ALS for my PhD. My research focus is on understanding the mechanisms behind the therapeutic effect of CDNF in different rodent models of ALS.
I joined the Voutilainen group in several years after my Master’s degree defense, and I am performing studies on the effect of Cerebral Dopamine Neurotrophic Factor, CDNF, on non-motor symptoms, which are involved with diseases such as Parkinson’s, Alzheimer’s and Huntington’s. I am currently working on methods, which can shows us the effect of CDNF on toxin and transgenic models of Huntington’s disease.
My background is biology (BSc in 2009, Saint-Petersburg State University) and neuroscience: from neuron to cognition (MSc in 2011, Saint-Petersburg State University), I am currently doing my PhD in Voutilainen's group.
My research focus is modelling Parkinson’s disease in rodents by overexpressing alpha-synuclein. I am interested in animal models of Parkinson’s disease and treatment with cerebral dopamine neurotrophic factor (CDNF).
Juho-Matti completed his Master's Degree in Pharmacology in the University of Helsinki, and is now doing his PhD on neurotrophic factors and Parkinson's Disease. He did a Roche Internship for Scientific Exchange in Basel, Switzerland, from 2017 to 2018.
My research interests include Parkinson’s disease (PD) and the cerebral dopamine neurotrophic factor (CDNF) as a novel therapeutic drug for the disease. I am currently studying the effects of CDNF in several alpha-synuclein models of PD.
I completed my Master’s degree in Neuroscience at University of Helsinki and I am currently pursuing my PhD in Voutilainen’s group.
I joined the Voutilainen group in 2018, with a research focus on the next generation neurotrophic factor MANF as a novel therapeutic in motor neuron disease. My current focus is into the development of MANF screening assays, the effects of MANF in patient-derived stem cells and animal models of ALS.
I graduated with a BSc (Hon) Medical Neuroscience, and MSc Neuroscience from the University of Sussex, UK. My research background is in neurodegenerative disease, having previously worked on plasmid generation in ALS, and cellular based assay development to screen novel drug compounds in a range of neurodegenerative disorders.
I began doing my Master’s thesis in Voutilainen group in 2017, and then continued working with the projects related to my PhD studies. My research interests are CDNF and Parkinson’s disease. I am studying the protective and restorative effects of CDNF, and related proteins, for nigrostriatal dopamine neurons using in vivo and in vitro methods. I am also interested in working with stem cells and understanding the mechanism and pharmacokinetics of CDNF.
Tuulikki can be contacted via her email: firstname.lastname@example.org
I am a master’s degree student in the University of Helsinki and I received my bachelor’s degree in biotechnology and chemical engineering in Metropolia University of Applied Science. I did my bachelor’s thesis on an individual identification quality control tool for genotyping unit at FIMM (Institute for Molecular Medicine Finland). I started in Voutilainen group in September 2017 as a laboratory technician. My main task’s are cell and stem cell culturing and maintenance of the laboratory, as well as quantification and analysis of samples from both in vivo and in vitro experiments.
I am studying molecular biosciences at the University of Helsinki in Viikki campus, and currently finishing my B.Sc studies. Since 2017 I have worked in Merja Voutilainen’s group as a research assistant, mainly helping Ph.D students and post-docs with a wide variety of tasks, including genotyping and IHC. My main interests are neurobiology and different neurodegenerative diseases, and I’m aiming to gain a broad knowledge in the field.
I am finishing my Bachelor studies in molecular bioscience at the University of Helsinki. I have been working in Voutilainen group since May 2017. Next autumn I am going for an exchange to do my Bachelor thesis at the University of Bern. I am really interested in neuroscience, and in the future I wish to continue studying neurodegenerative diseases.
I completed my undergraduate degree in Biology at the Viikki campus here in Helsinki, and am currently doing my Master's degree in Translational Medicine at the Faculty of Medicine at Meilahti.
I am interested in uncovering disease mechanisms and developing treatments to complicated pathologies. At Voutilainen group I am participating in the development of patient specific human induced pluripotent stem cell-derived neurons that can be used in the study of treatments for Parkinson's disease and ALS. I am also assisting in several animal experiments, which aim to analyze the effects of several neurotrophic factors on different neurodegenerative diseases.
I'm a student of Metropolia University of Applied Sciences, and I am writing my thesis on PD. My keen interests are histology and neurobiology. As a research technician, I feel privileged to help our researchers with their ambitious work to understand the functions of neurodegenerative diseases, such as ALS and PD, and finding key solutions for treating them.
I am a student in the Metropolia University of Applied Sciences and I began writing my bachelor's thesis in the Voutilainen group in 2018. My main focuses in Voutilainen group are neurotrophic factors and their pharmacokinetics in Parkinson’s disease. What really interests me is the prospect of finding something to advance the management of neurodegenerative diseases (such as PD and ALS) which in future will be able to better relieve pain or possibly even save lives.
Roope Nupponen can be contacted via his email: email@example.com
- Smita Saxena, University of Bern
- Michael Sendtner, University of Würzburg
- Patrick Mehlen, University of Lyon
- Brandon Harvey, NIH, NIDA